« Back to Record
Citation APA

Hanker, A. A., Frampton, G. G., Sanford, E., Owens, P., Becker, J., Groseclose, R. M., Castellino, S., Joensuu, H., Huober, J., Brase, J. C., Majjaj, S., Garrett, J. J., Brohée, S., Venet, D., Brown, D. N., Baselga, J., Piccart-Gebhart, M., Sotiriou, C., Arteaga, C. L., Estrada, M. V., Moore, P. P., Ericsson, P. G., Koch, J. J., Langley, E., Singh, S., & Kim, P. P. (2017). HER2-overexpressing breast cancers amplify FGFR signaling upon acquisition of resistance to dual therapeutic blockade of HER2. Clinical cancer research, 23(15), 4323-4334. doi:10.1158/1078-0432.CCR-16-2287


Permalink

http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/259216

Hanker, A. A., Frampton, G. G., Sanford, E., Owens, P., Becker, J., Groseclose, R. M., Castellino, S., Joensuu, H., Huober, J., Brase, J. C., Majjaj, S., Garrett, J. J., Brohée, S., Venet, D., Brown, D. N., Baselga, J., Piccart-Gebhart, M., Sotiriou, C., Arteaga, C. L., Estrada, M. V., Moore, P. P., Ericsson, P. G., Koch, J. J., Langley, E., Singh, S., & Kim, P. P. (2017). HER2-overexpressing breast cancers amplify FGFR signaling upon acquisition of resistance to dual therapeutic blockade of HER2. Clinical cancer research, 23(15), 4323-4334. doi:10.1158/1078-0432.CCR-16-2287